Increasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role in clinical trials and the potential impact of expanded use.
Bristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, showing that more than a quarter of patients were alive after fiv
US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the FDA agreed to a fast review in follicular lymphoma.
NICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) in untreated kidney cancer, citing uncertainties about its lon
High-profile digital health investor Luba Greenwood recently announced that she’s joined as Chair of the Board at Closed Loop Medicine, a company applying machine learning to precision drug